Literature DB >> 29681597

Strategy for Cardiovascular Surgery in Patients with Antithrombin III Deficiency.

Yoshiyuki Nishimura1, Yasushi Takagi2.   

Abstract

Antithrombin III (ATIII) deficiency is a rare disorder in which thrombosis can be induced by stimuli that do not usually lead to thrombus formation, including minor injuries and surgery. Therefore, patients with ATIII deficiency undergoing cardiovascular surgery that involves heparinization require careful perioperative management. We experienced five patients with ATIII deficiency who underwent cardiovascular surgery and were managed with ATIII replacement. By administration of ATIII concentrate, preoperative ATIII activity was maintained at ≥120% and postoperative ATIII activity at ≥80%. All five patients were treated successfully without postoperative complications such as hemorrhage or thrombosis. In patients with ATIII deficiency undergoing cardiac surgery, it is important to perform ATIII replacement to achieve preoperative ATIII activity ≥120% and postoperative ATIII activity ≥80%, while the activated clotting time (ACT) is maintained at >400 seconds during cardiopulmonary bypass. In addition, long-term postoperative anticoagulant therapy is necessary in hereditary ATIII deficiency patients with a history of thrombosis.

Entities:  

Keywords:  antithrombin III deficiency; cardiovascular surgery

Mesh:

Substances:

Year:  2018        PMID: 29681597      PMCID: PMC6102604          DOI: 10.5761/atcs.oa.18-00030

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  10 in total

1.  INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.

Authors:  O EGEBERG
Journal:  Thromb Diath Haemorrh       Date:  1965-06-15

2.  Surgical treatment of atrial septal defect in a patient with familial antithrombin-III deficiency.

Authors:  Tsutomu Hattori; Mitsumasa Hata; Akira Sezai; Shinji Wakui; Motomi Shiono
Journal:  Ann Thorac Cardiovasc Surg       Date:  2012-11-15       Impact factor: 1.520

3.  Mortality and causes of death in inherited antithrombin deficiency.

Authors:  H H van Boven; J P Vandenbroucke; R G Westendorp; F R Rosendaal
Journal:  Thromb Haemost       Date:  1997-03       Impact factor: 5.249

4.  Early graft thrombosis due to antithrombin III deficiency following CABG.

Authors:  P Kovacevic; L Velicki; N Komazec; B Vujin; V Ivanovic; M Golubovic
Journal:  Herz       Date:  2011-02-18       Impact factor: 1.443

5.  Postoperative antithrombin levels and outcome in cardiac operations.

Authors:  Marco Ranucci; Alessandro Frigiola; Lorenzo Menicanti; Antonio Ditta; Alessandra Boncilli; Simonetta Brozzi
Journal:  Crit Care Med       Date:  2005-02       Impact factor: 7.598

Review 6.  Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update.

Authors:  George M Rodgers
Journal:  Thromb Haemost       Date:  2009-05       Impact factor: 5.249

7.  [Annuloaortic ectasia associated with antithrombin III deficiency; report of a case].

Authors:  Yasue Fujiwara; Tomoyuki Yamada; Kazuhiko Katsuyama; Takahiko Utsumi
Journal:  Kyobu Geka       Date:  2013-07

8.  [Heparin resistance during cardiopulmonary bypass].

Authors:  Ryoko Maeda; Hirokazu Fukuda; Yasushi Nakaigawa; Masahiro Hiruta; Yoshihiro Hirabayashi; Norimasa Seo
Journal:  Masui       Date:  2003-09

9.  Coronary artery bypass surgery in patients with inherited antithrombin deficiency.

Authors:  P Clark; I D Walker; R F Neilson
Journal:  Br J Haematol       Date:  1995-06       Impact factor: 6.998

10.  Antithrombin after cardiac surgery: implications on short and mid-term outcome.

Authors:  Domenico Paparella; Giangiuseppe Cappabianca; Giuseppe Scrascia; Giuseppe Fiore; Andreas Paramythiotis; Nicola Di Bari; Maria Pia Trisorio Liuzzi; Mohamed F Ibrahim; Tommaso Fiore; Luigi de Luca Tupputi Schinosa
Journal:  J Thromb Thrombolysis       Date:  2008-01-11       Impact factor: 2.300

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.